Camurus, Braeburn deal

Camurus granted Braeburn exclusive, North American rights to buprenorphine injection depot ( CAM2038) to treat opioid addiction and pain and option rights in Japan, Korea, Taiwan and China. Camurus will receive $20 million up front and is eligible for up to $35 million in development milestones for opioid dependence and up to $21 million in development milestones for pain. Camurus is also eligible for mid-teen royalties and up to $75 million in sales milestones. ...